RxDoctor Payments Data

Himakshi Bhatt, OD

Optometrist · Atlanta, GANPI 1356913347

Payments from drug & device makers

$4,616in general payments, 2019–2025

Across 107 payments — averaging $43.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$878
  • Sun Pharmaceutical Industries Inc.$727
  • Alcon$565
  • Bausch & Lomb Americas Inc.$417
  • Oyster Point Pharma, Inc.$329
  • AbbVie$318
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,616100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,616 in reported general payments places this provider in the 85th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$67,438
Medicare patients
285
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine136$176,024
XiidraLifitegrast153$169,785
CequaCyclosporine38$47,607
LumiganBimatoprost72$44,447
MieboPerfluorohexyloctane/Pf55$41,711
RocklatanNetarsudil Mesylat/Latanoprost48$27,701
Cyclosporine27$16,688
VyzultaLatanoprostene Bunod22$10,087
EysuvisLoteprednol Etabonate16$7,956
SimbrinzaBrinzolamide/Brimonidine Tart34$7,168
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$5,327
CombiganBrimonidine Tartrate/Timolol20$3,734
Loteprednol Etabonate26$3,263
Prednisolone Acetate58$2,447
ErythromycinErythromycin Base158$1,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$318$224,204228 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$417$221,584230 claims
Sun Pharmaceutical Industries Inc.Cequa$727$47,60738 claims
Kala Pharmaceuticals, Inc.Eysuvis$52$7,95616 claims
AlconSimbrinza$565$7,16834 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$14$3,26326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →